Skip to main content
Annovis Bio, Inc. logo

Annovis Bio, Inc. — Investor Relations & Filings

Ticker · ANVS ISIN · US03615A1088 LEI · 549300IFBVI51FN3NJ32 US Professional, scientific and technical activities
Open in API
Filings indexed 290 across all filing types
Latest filing 2023-04-11 Director's Dealing
Country US United States of America
Listing US ANVS

About Annovis Bio, Inc.

https://www.annovisbio.com/

Annovis Bio, Inc. is a clinical-stage drug platform company that develops therapies for neurodegenerative diseases. The company's primary focus is on conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead product candidate, buntanetap, is a translational inhibitor designed to halt the death of nerve cells by targeting the synthesis of multiple neurotoxic proteins. The company's therapeutic approach aims to restore nerve cell function, with the goal of improving cognitive and motor abilities in patients suffering from neurodegeneration.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2023-04-11 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-04-11 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-04-11 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-04-11 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the termination of a material definitive agreement related to an ATM Equity Offering Sales Agreement and provides details about the termination and prior sales under the agreement. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a presentation, call transcript, or voting result announcement. It is a regulatory filing reporting a significant corporate event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 4433 characters, which is consistent with a typical 8-K filing. Confidence is high due to the clear identification of the form and content type.
2023-04-04 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report under the Securities Exchange Act of 1934. The content describes the entry into a material definitive agreement related to an ATM Equity Offering Sales Agreement for up to $50 million of common stock. It includes details about the sales agreement, the parties involved, and related exhibits such as the sales agreement and legal opinion. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is an announcement of a capital raising activity and financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just a brief announcement or reference to another report.
2023-04-03 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.